Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LTC004 + regorafenib
- Development stage
- Phase 2
- Lead developer
- Bayer
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Intravenous
01
Overview
LTC004 + regorafenib is a combination therapy being developed by Beijing Zhidao Biological Technology Co., Ltd. for the treatment of metastatic colorectal cancer (mCRC). LTC004 is a biologic agent that acts as a dual Interleukin-2 receptor (IL-2R) and Interleukin-15 receptor (IL-15R) agonist, designed to stimulate immune cell proliferation and activity. Regorafenib (brand name Stivarga) is an oral multi-kinase inhibitor that targets multiple receptor tyrosine kinases involved in angiogenesis (VEGFR1-3, TIE2), oncogenesis (KIT, RET, BRAF), and metastasis (PDGFR-β, FGFR). The combination is currently in Phase II clinical development, evaluating the safety and preliminary efficacy in patients with mCRC who have failed standard treatments.
- Other names
- LTC004 + regorafenib
02
Targets
RAF (RAF family kinase)FGFR (FGFR family)IL-2Rβγ (Interleukin-2 receptor subunit beta/common gamma chain complex)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)BRAF (B-Raf proto-oncogene, serine/threonine kinase)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on LTC004 + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LTC004 + regorafenib.